|Bid||0.000 x 3000|
|Ask||1.210 x 800|
|Day's Range||0.9500 - 1.0100|
|52 Week Range||0.8900 - 2.0500|
|Beta (3Y Monthly)||3.95|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.50|
MELBOURNE, Australia, Sept. 17, 2018-- Hainan Resort Software Community has on behalf of Hainan Ecological Smart City Group formally extended an invitation to Genetic Technologies Limited to establish ...
NEW YORK, NY / ACCESSWIRE / July 17, 2018 / Genetic Technologies saw big gains on news that its breast cancer and colorectal cancer risk assessment tests are on track. Shares of Innovate were headed in the opposite direction on news that the company has filed a securities registration statement amendment with the SEC to issue up to $175 million of new stock and to sell 14 million shares of existing stock. Innovate Biopharmaceuticals, Inc.
Today, Genetic Technologies (GENE) was trading over 70% higher than yesterday’s closing price of $1.09. The stock jumped ~72.5% in premarket trading. The stock price and volumes rose on the news of the company’s on-track breast cancer and colorectal cancer risk assessment tests, slated for release in October.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Coda Octopus Group, Inc. (NASDAQ: CODA ) stock soared ...
Beyond 30,000, that’s where the Dow Jones Industrial Average (DJIA) is headed, according to Gene Simmons, known by many rock n’ roll fans as the KISS Demon. As of the close of trading on Tuesday, the Dow was sitting around 24,360, down 1.5% on the year. Since 1985, the Dow has gone through good times and bad, but has risen overall by nearly 1,800%.
TORONTO , March 20, 2018 /CNW/ - Dan Kriznic , Chairman, CEO, Founder & Director, alongside Gene Simmons , Co-Founder of KISS, and Chief Evangelist Officer, Invictus MD Strategies Corp. (GENE), joined ...
NASDAQ: GENE) to accelerate the prediction of cancer for millions of individuals worldwide. GTG, whose lead product is BREVAGenplus® - a clinically validated risk assessment test for non-hereditary breast cancer - is at the forefront of preventive medicine.